A collection of injector pens for the Wegovy weight loss drug is displayed in an illustrative photo. Analysts suggest that health insurance schemes may expand coverage for Wegovy following the results of a late-stage trial that demonstrated its effectiveness in reducing major cardiovascular events. The “SELECT” trial conducted by Novo Nordisk exceeded expectations by showing a 20% reduction in the risk of heart attacks and strokes compared to a placebo. Novo Nordisk plans to seek approval from regulators to add cardiovascular benefits to the drug’s label. This breakthrough could change the perception of Wegovy from a cosmetic drug to one that health insurers are willing to fund. Previously, coverage for the drug was limited due to its high costs and lack of evidence regarding its health benefits. However, the results of this trial could alter that, resulting in increased access and reimbursement for patients. The global obesity epidemic and the high prevalence of cardiovascular diseases make this a potentially significant development. The weight-loss drug market is projected to reach $200 billion in the next decade, and Novo Nordisk is poised to become Europe’s most valuable company, surpassing luxury goods giant LVMH. The lack of competition in this market further supports their position. Supply constraints pose a challenge as demand for the drug surges. Novo Nordisk and Eli Lilly have urged physicians to limit prescriptions to patients with medical needs due to the spike in orders, potentially causing shortages that may extend into 2024. It is believed that the current risk-benefit profile of these drugs is positive overall, despite concerns about side effects. However, it may take some time for supply to meet demand.
Denial of responsibility! VigourTimes is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
